Tag Archives: solid tumor

Lyell and CRISPR Tx Present Novel CAR-Ts in Solid Tumors; SITC 2023 Analysis 2

SITC 2023 Analysis 2: Lyell and CRISPR Tx presented preclinical results from their novel cell therapies in solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Allogene Doses First Patients With ALLO-316 (CD70 CAR-T) and Presents Novel TurboCARs for Solid Tumors; bluebird’s Oncology Newco Renamed as 2seventy bio; Allogene and bluebird bio Q1 2021 Earnings Call Summaries

On Wednesday, May 5, Allogene held their Q1 2021 earnings call (press release) highlighting the initiation of ALLO-316’s Ph1 TRAVERSE trial in renal cell carcinoma (RCC) and provided several updates across their CAR-T programs. On the same day, bluebird bio reported their Q1 2021 results (press release) and confirmed that the oncology Newco will be called 2seventy while highlighting Abecma’s FDA approval in ≥5L MM. Below, Celltelligence provides insights on how Allogene may strategically advance their CAR-T programs while discussing Allogene’s growing potential in the solid tumor setting with their TurboCAR platform. Furthermore, Celltelligence will discuss 2seventy bio’s corporate structure while commenting on Abecma’s potential EU approval timeline.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.